NCT04750460View on ClinicalTrials.gov

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

February 16, 2022

Study Completion Date

February 16, 2022

Conditions
Secondary HyperparathyroidismChronic Kidney Disease-Mineral and Bone DisorderDialysisHypocalcemiaHypoparathyroidism
Interventions
DRUG

Teriparatide

Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.

Trial Locations (1)

190103

Saint-Petersburg State University Hospital, Saint Petersburg

All Listed Sponsors
lead

Saint Petersburg State University, Russia

OTHER

NCT04750460 - Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). | Biotech Hunter | Biotech Hunter